Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (361-370 of 391) with videos related to

Pageof 40
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
The Lancet. Neurology|September 20, 2025
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Neurology|April 12, 2022
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry StudyMarianna Vitkova, Ibrahima Diouf, Charles Malpas, et al.
Pageof 40

Showing results (361-370 of 391) with videos related to

Sort By:
Pageof 40
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
The Lancet. Neurology|September 20, 2025
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Neurology|April 12, 2022
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry StudyMarianna Vitkova, Ibrahima Diouf, Charles Malpas, et al.
Pageof 40